List of Excipients in Branded Drug AKTEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	AKTEN	lidocaine hydrochloride	17478-792	HYDROCHLORIC ACID
Akorn	AKTEN	lidocaine hydrochloride	17478-792	HYPROMELLOSES
Akorn	AKTEN	lidocaine hydrochloride	17478-792	SODIUM CHLORIDE

AKTEN Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 21, 2026

AKTEN is a prescription ophthalmic anesthetic containing lidocaine hydrochloride 3% in a sterile gel. Its commercial differentiation depends more on ocular tolerability, residence time, single-use packaging, and manufacturing controls than on the lidocaine molecule itself. The strongest opportunities are preservative-free unit-dose delivery, optimized gel rheology, ready-to-use procedural kits, and differentiated 505(b)(2) products. Generic entry risk is material because lidocaine is an established active ingredient, while formulation and device attributes may create narrower barriers.

What is AKTEN and what is its FDA status?

AKTEN is a sterile ophthalmic gel indicated for topical anesthesia of the ocular surface during ophthalmic procedures. The product contains 30 mg/mL lidocaine hydrochloride and is administered by eye-care professionals rather than dispensed as a chronic-use patient medicine.[1]

Attribute	AKTEN
Active ingredient	Lidocaine hydrochloride
Strength	3%, equivalent to 30 mg/mL
Dosage form	Ophthalmic gel
Route	Topical ocular
FDA pathway	505(b)(1) NDA
NDA	NDA 201623
Initial FDA approval	2012
Primary use	Topical anesthesia during ophthalmic procedures
Preservative status	Preservative-free presentation
Commercial format	Single-use ophthalmic container
Therapeutic category	Local anesthetic, ophthalmic

AKTEN is distinct from injectable lidocaine, lidocaine ophthalmic solutions, and compounded ophthalmic anesthetics. The gel format is intended to provide local anesthesia while remaining on the ocular surface long enough to support procedural use.

What excipients are used in AKTEN?

The FDA prescribing information identifies hypromellose, sodium chloride, citric acid, sodium citrate dihydrate, and water for injection as inactive ingredients.[1]

Excipient	Likely formulation role
Hypromellose	Gelling, viscosity control, ocular surface residence
Sodium chloride	Tonicity adjustment
Citric acid	pH adjustment and buffering
Sodium citrate dihydrate	Buffer capacity and pH control
Water for injection	Sterile vehicle

The formulation strategy is relatively concentrated: one principal viscosity-building polymer, a sodium chloride tonicity component, and a citrate buffer system. The absence of a conventional preservative supports single-use packaging and reduces exposure to preservative-related ocular-surface toxicity.

Why hypromellose is commercially important

Hypromellose is the key functional excipient in AKTEN. It controls viscosity, spreadability, retention, and the tactile characteristics of the gel. A higher-viscosity product may remain on the cornea longer but can cause transient blur, stringiness, or delayed clearance. A lower-viscosity product may be easier to administer but may reduce residence time.

For a competing product, the most important development variables are:

• Polymer concentration and molecular-weight grade
• Gel viscosity across the ophthalmic temperature range
• Drop or ribbon formation from the container
• Optical clarity
• Lidocaine release from the gel matrix
• Corneal retention
• Tear-film dilution behavior
• Sterility after opening or dose withdrawal
• Ocular irritation and epithelial compatibility

A direct substitution of another cellulose derivative would not automatically create a commercially equivalent product. Methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, carbomer, poloxamer, and hyaluronic-acid systems can produce materially different rheology and ocular tolerability profiles.

What formulation characteristics protect AKTEN commercially?

AKTEN’s defensibility is likely concentrated in the combined product architecture rather than in the active ingredient. The relevant commercial attributes are:

1. A 3% lidocaine ophthalmic gel.
2. Preservative-free delivery.
3. Sterile single-use packaging.
4. A hypromellose-based vehicle.
5. A buffer and tonicity system compatible with ocular use.
6. Procedure-specific dosing and handling.

The combination can create practical barriers even where broad composition claims are difficult to maintain. A competitor may avoid direct patent overlap but still face development requirements involving sterility, extractables and leachables, container closure integrity, ophthalmic irritation, assay uniformity, and comparative performance.

What formulations could compete with AKTEN?

Potential competitive formulations include:

Formulation concept	Commercial rationale	Main development risk
Hypromellose gel with altered polymer grade	May improve spreadability or retention	Equivalence and rheology differences
Carbomer-based gel	Higher viscosity at low concentration	Blur, irritation, difficult administration
Poloxamer thermoresponsive gel	Low viscosity during dosing with in situ thickening	Manufacturing complexity and ocular tolerability
Hyaluronic-acid gel	Lubricity and surface retention	Cost, stability, and lidocaine release
Preservative-free solution	Easier manufacturing and administration	Shorter residence time
Lidocaine-plus-adjuvant gel	Potentially longer or stronger anesthesia	New clinical and safety requirements
Unit-dose sterile ampoule	Improved packaging flexibility	Dose extraction and contamination controls
Preloaded procedural applicator	Workflow differentiation	Device combination-product requirements

A competing formulation does not need to reproduce every AKTEN characteristic. A product that provides faster onset, less blur, easier application, or lower procedural waste could compete even with shorter ocular residence.

When does AKTEN lose exclusivity?

AKTEN does not have biologic exclusivity, so biosimilar timing is not relevant. The principal regulatory threats are an ANDA referencing the product as a reference listed drug, a 505(b)(2) application, or nonprescription compounded alternatives where legally permitted.

FDA approval in 2012 does not by itself establish the current end of all market protection. The relevant dates depend on:

• The NDA’s regulatory exclusivity period
• Any listed patents in the Orange Book
• Patent-term adjustments or extensions
• Pediatric exclusivity
• Litigation stays triggered by Paragraph IV certification
• Whether an applicant uses an ANDA or 505(b)(2) pathway

For small-molecule products, five-year new chemical entity exclusivity generally applies only where the active moiety has not previously been approved. Lidocaine had been approved decades before AKTEN, making a new five-year NCE period unlikely. Three-year exclusivity could apply only if the approval relied on qualifying new clinical investigations essential to approval, and that protection would be limited to the approved change rather than the entire lidocaine market.[2]

The practical commercial conclusion is that AKTEN’s market protection depends primarily on patent listings, product-specific formulation differentiation, manufacturing know-how, and customer adoption.

What is the Orange Book status of AKTEN?

The Orange Book is the controlling source for listed patents, exclusivity, therapeutic-equivalence coding, and reference-product information.[2] AKTEN should be evaluated under NDA 201623 using the current FDA Orange Book data rather than relying on third-party patent summaries.

The relevant questions for an ANDA applicant are:

• Whether NDA 201623 remains the reference listed drug
• Whether any patents are currently listed
• Whether listed patents cover composition, formulation, method of use, or a device
• The expiration date of each listed patent
• Whether the patents are subject to Paragraph IV certification
• Whether a 30-month litigation stay is available
• Whether any patent is listed only for a method of use

The absence of a broad active-ingredient patent would not eliminate risk. A formulation patent covering a gel matrix, concentration range, preservative-free presentation, or ocular-use method could still delay an ANDA or require a design-around.

What Paragraph IV challenges could target AKTEN?

An ANDA applicant could challenge listed patents through a Paragraph IV certification. The most plausible challenge theories would focus on:

• Lack of novelty in a lidocaine ophthalmic gel
• Obviousness based on known lidocaine ophthalmic products and viscosity agents
• Written-description or enablement defects
• Claim scope exceeding the disclosed formulation
• Non-infringement through a different polymer, buffer, container, or concentration
• Invalidity of method-of-use claims based on earlier ophthalmic anesthesia procedures

The strongest defense would normally require evidence that the claimed combination produced an unexpected result, such as a meaningful improvement in ocular retention, anesthetic onset, tolerability, or procedural performance.

A Paragraph IV strategy is less attractive if the patent estate is narrow and the applicant can obtain approval through a formulation design-around. In that situation, a 505(b)(2) pathway could be more practical than a direct ANDA, particularly if the proposed product differs in excipients, dosage form, dosing instructions, or clinical performance.

What patent claims could protect an AKTEN-like product?

A robust patent program would divide protection across several claim categories.

Composition claims

Potential claim elements include:

• Lidocaine hydrochloride concentration
• Hypromellose concentration and viscosity range
• Citrate buffer concentration
• Sodium chloride range
• pH and osmolality
• Preservative-free status
• Sterile ophthalmic gel characteristics

Broad claims covering lidocaine and hypromellose may face prior-art and obviousness challenges. Narrower claims tied to measured rheology, release behavior, or a defined pH and osmolality profile may be more defensible but are easier to design around.

Method-of-use claims

Potential methods include use during:

• Cataract surgery
• Intravitreal injection
• Corneal procedures
• Tonometry
• Gonioscopy
• Laser procedures
• Foreign-body removal
• Minor ophthalmic interventions

Method claims may provide commercial value where the product is used across several procedures. Their enforcement can be difficult if the claim depends on physician behavior that is not readily observable.

Formulation-performance claims

These claims could focus on:

• Corneal residence time
• Anesthetic onset
• Duration of numbness
• Reduced epithelial toxicity
• Reduced visual disturbance
• Low-dose delivery
• Improved retention compared with lidocaine solution

Performance claims require strong comparative data. They are more valuable when linked to objective testing and clinically meaningful outcomes.

Container and device claims

Packaging claims could cover:

• Single-use sterile tubes
• Unit-dose ampoules
• Metered-dose applicators
• Non-dripping tips
• Low-dead-volume delivery
• Container closure systems that preserve sterility
• Applicators integrated into ophthalmic procedure kits

Device protection may be particularly useful if a formulation design-around is straightforward.

How strong is the AKTEN patent estate?

The active ingredient provides limited protection because lidocaine is long established. The likely strength of the estate depends on the availability and scope of product-specific patents, not on molecule-level exclusivity.

Protection layer	Relative strategic value	Vulnerability
Lidocaine molecule	Low	Expired prior-art field
3% ophthalmic use	Moderate	Earlier ophthalmic anesthetic disclosures
Hypromellose gel	Moderate	Known excipient technology
Specific excipient ranges	Moderate to high	Design-around possible
Preservative-free sterile package	Moderate	Packaging alternatives
Method-of-use claims	Moderate	Enforcement and prior-art issues
Device or applicator	Moderate to high	Depends on implementation
Manufacturing process	High as know-how	Difficult to reverse engineer
Clinical performance data	High commercially	May not create standalone exclusivity

The strongest practical moat may be process control. Sterile ophthalmic gels can present challenges involving polymer hydration, mixing order, deaeration, filtration or aseptic processing, viscosity uniformity, filling, and container closure integrity. A competitor may be able to reproduce the ingredients but struggle to reproduce the same manufacturing performance.

What manufacturing and IP barriers affect competing products?

A generic or follow-on product must control several technical risks:

• Sterile processing of a viscous formulation
• Uniform lidocaine distribution
• Polymer hydration without agglomeration
• Control of air entrapment
• Consistent extrusion or drop formation
• Stability under temperature cycling
• Compatibility with the primary container
• Low extractables and leachables
• Sterility through the labeled shelf life
• Accurate fill volume in a single-use package

The most defensible manufacturing know-how may involve polymer addition sequence, hydration time, mixing energy, temperature control, pH adjustment order, and filling conditions. These process parameters can support trade-secret protection even where composition patents are narrow.

What commercial opportunities exist for excipient innovation?

Preservative-free procedural platforms

A company could develop a platform of preservative-free ophthalmic anesthetics using different polymers and unit-dose systems. The platform could target ophthalmology practices seeking lower waste, simpler inventory, and reduced preservative exposure.

Procedure-specific viscosity

Different procedures may favor different rheological profiles. A low-viscosity product could target rapid application and reduced blur. A higher-viscosity product could target procedures requiring longer surface retention.

Combination procedural kits

AKTEN could be incorporated into sterile kits containing:

• Lidocaine gel
• Speculum or applicator
• Antiseptic preparation
• Lubricant
• Procedure-specific accessories

Kit-based commercialization may increase switching costs and simplify purchasing. It also introduces device, labeling, reimbursement, and supply-chain complexity.

505(b)(2) follow-on products

A follow-on product could use the established lidocaine safety database while pursuing a differentiated formulation or delivery system. Potential advantages include:

• Shorter development than a novel active ingredient
• Ability to rely partly on published literature or FDA findings
• Product-specific clinical claims
• Opportunities for three-year exclusivity if qualifying new clinical investigations support approval

The risk is that a 505(b)(2) product may still require clinical bridging, comparative local-tolerance studies, and a detailed justification for differences from the reference product.

International expansion

The U.S. product strategy may not transfer directly to Europe, Canada, Japan, or emerging markets. Each jurisdiction may apply different rules for:

• Ophthalmic anesthetic classification
• Preservative-free claims
• Sterility validation
• Patent linkage
• Data exclusivity
• Medical-device combination status
• Compounding and hospital procurement

A regional strategy should separate formulation patents, use patents, packaging claims, and manufacturing know-how. Patent filings should precede commercial disclosure and should cover both the core gel and commercially realistic design-arounds.

Which companies could challenge or compete with AKTEN?

Competition is likely to come from several groups rather than a single direct generic entrant:

1. Generic pharmaceutical companies with sterile ophthalmic manufacturing capacity.
2. Ophthalmic specialty companies developing procedural products.
3. Compounding pharmacies supplying lidocaine ophthalmic preparations where permitted.
4. Device companies selling integrated ophthalmic anesthesia systems.
5. Manufacturers of lidocaine ophthalmic solutions and gels in non-U.S. markets.
6. Specialty distributors offering lower-cost procedure kits.

The most credible challenger will need more than lidocaine sourcing. It will need validated sterile ophthalmic manufacturing, an acceptable container closure system, regulatory capability, and access to ophthalmology practices.

What litigation and settlement risks affect AKTEN?

Patent litigation risk depends on current Orange Book listings and any ANDA notice letters. A Paragraph IV dispute could lead to:

• Patent infringement litigation under Hatch-Waxman
• A 30-month approval stay
• At-risk generic launch after certification
• Settlement with a licensed entry date
• Authorized-generic arrangements
• Covenants not to sue
• Restrictions on formulation or indication labeling

No litigation conclusion should be drawn from the existence of a patent alone. The commercial impact depends on claim scope, remaining patent term, litigation timing, injunction risk, and the applicant’s ability to launch a non-infringing alternative.

What is the revenue exposure from generic entry?

AKTEN revenue is exposed to substitution risk because the active ingredient is inexpensive and the product is used in procedural settings. Price competition could be significant if a generic matches the dosage form, sterility, preservative-free status, and handling profile.

The likely market effects are:

Entry scenario	Expected commercial effect
No direct generic, but compounded alternatives	Price pressure in cost-sensitive practices
Solution-based generic	Limited substitution if gel residence is clinically preferred
Same-gel generic	Significant price erosion and formulary pressure
Multiple sterile-gel entrants	Rapid commoditization
Differentiated device or kit entrant	Segment-specific share loss
505(b)(2) product with improved performance	Potential premium competition

The product’s commercial resilience will depend on physician preference, procedure workflow, purchasing contracts, distributor relationships, and whether the gel is viewed as clinically interchangeable with lower-cost alternatives.

Key Takeaways

• AKTEN is a 3% preservative-free lidocaine hydrochloride ophthalmic gel approved under NDA 201623.
• Its disclosed excipients are hypromellose, sodium chloride, citric acid, sodium citrate dihydrate, and water for injection.
• Hypromellose is the principal functional excipient and controls residence time, viscosity, spreadability, and administration characteristics.
• Lidocaine itself provides little meaningful exclusivity because it is an established active ingredient.
• The main protection opportunities are formulation ranges, rheology, ocular-use methods, packaging, delivery devices, and manufacturing know-how.
• The principal regulatory threats are ANDA, Paragraph IV, 505(b)(2), and legally permitted compounded alternatives.
• Biosimilar risk does not apply because AKTEN is a small-molecule drug, not a biologic.
• The strongest commercial opportunities are preservative-free unit-dose systems, procedure-specific viscosity, integrated kits, and differentiated 505(b)(2) products.
• Current Orange Book listings and litigation records should control any precise patent-expiration or launch-date analysis.

FAQs

Can a competitor use the same lidocaine concentration but a different polymer?

Yes. A different polymer may support an ANDA or 505(b)(2) strategy, depending on the reference-product requirements, formulation differences, patent claims, and FDA’s determination of pharmaceutical equivalence or clinical bridging.

Is hypromellose required to make an AKTEN-equivalent product?

No. Hypromellose is the disclosed gelling excipient, but a competitor could evaluate other polymers. The substitute must meet ophthalmic safety, sterility, stability, viscosity, release, and performance requirements.

Could a preservative-free AKTEN competitor receive three-year exclusivity?

Potentially, but only if the FDA approval relies on qualifying new clinical investigations essential to approval. A formulation change alone does not automatically create three-year exclusivity.

Does a single-use tube create patent protection by itself?

No. Single-use packaging may be patentable when combined with novel structural or functional features, but the commercial barrier may arise from sterility validation, container closure integrity, manufacturing controls, and customer workflow rather than from packaging alone.

Can a compounded lidocaine ophthalmic gel replace AKTEN?

Compounded products may compete in some settings, but they do not automatically provide the same FDA-approved labeling, commercial sterility assurance, standardized manufacturing, packaging controls, or procurement profile as AKTEN.

References

1. U.S. Food and Drug Administration. (2012). AKTEN (lidocaine hydrochloride ophthalmic gel) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format of an ANDA.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
5. U.S. Food and Drug Administration. (2020). Inactive ingredient database.